GoodRx Holdings Inc (GDRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$3.48-1.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · GDRX
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.48 GDRX trades at 12× p/e, below its 20× p/e peer median. Our $6.59 fair value sits well above the price. We hold it with low confidence: our number sits well above the analyst range and quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Analysts target $3.75–$5.00. Note: our $6.59 fair value sits above the entire analyst range ($3.75–$5.00). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $4.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $20.93 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $29.61 | — | — | Hist. CAGR | high |
| graham number | 12M | $3.42 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$3.75 – $5.00 (median $4.00) · 4 analysts · as of 2026-08-20
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 27% over what the business is worth with no growth; closing that gap needs roughly 12.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $0.11/sh owner earnings.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $4.22 |
| 10.1 |
| 0.47 |
| TTM |
| high |
| Peer P/FCF | 12M | $6.53 | 15.6 | 0.42 | TTM | high |
| Peer P/E | 12M | $5.70 | 20.4 | 0.28 | TTM | high |
| Peer P/S | 12M | $4.31 | 1.9 | 2.26 | TTM | high |
| PEG | 12M | $7.71 | 27.5 | 0.28 | TTM | high |
| residual income | 12M | $2.42 | — | — | TTM | high |
| triangulated | 12M | $5.52 | 20.4 | 0.27 | Triangulated | high |
| Peer P/FCF | 3Y | $9.92 | 15.6 | 0.64 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $7.46 | 20.4 | 0.37 | Analyst | medium |
| Peer P/S | 3Y | $4.74 | 1.9 | 2.48 | guidance | medium |
| PEG | 3Y | $10.08 | 27.5 | 0.37 | Analyst | medium |
| Peer P/FCF | 5Y | $13.13 | 15.6 | 0.84 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $7.69 | 20.4 | 0.38 | Analyst | medium |
| Peer P/S | 5Y | $4.89 | 1.9 | 2.56 | guidance | medium |
| PEG | 5Y | $10.40 | 27.5 | 0.38 | Analyst | medium |